Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polysaccharide Antibody Response Study
2014-003007-29Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of salmonella typhi capsular polysaccharide vaccine and Pneumo 23 in selective antibody deficiency (SAD) (2 arms), sponsored by UZ Leuven. Primary endpoint: Diagnostic performance of low Salmonella typhi capsular Vi response. Started Jul 2015; status: completed.
02
Drugs
salmonella typhi capsular polysaccharide vaccinePneumo 23
03
Conditions
selective antibody deficiency (SAD)
Beyond the preview
Go deeper on 2014-003007-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003007-29.